mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
A legfontosabb adatok
- Ki végzi
- Alliance for Clinical Trials in Oncology
- Hol
- Bayamón, Manati és San Juan (Puerto Rico)Mind a 7 helyszín megnézéseMég 1 másik országban, 795 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 382 fő, tervezett
- Kezdés
- 2023. jan. 31.
- Várható befejezés
- 2028. nov. 8.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Fluorouracil
- Leucovorin Calcium
- Oxaliplatin
- Irinotecan
- Nivolumab
- Magnetic Resonance Imaging
- Computed Tomography
- Biospecimen Collection
- Questionnaire Administration
- A regiszteradat frissítve
- 2026. november 3.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek HER2-negatív daganata van a nyelőcsőben, a gyomorban vagy a kettő találkozásánál, és ez műtéttel nem eltávolítható vagy szétterjedt. Ennek a előrehaladott betegségnek a kezelését még nem kezdték el.
- Életkor
- 18 éves vagy idősebb
- Nem
- Férfiak és nők is részt vehetnek
- A betegség stádiuma
- Nyelőcső, nyelőcső–gyomor átmenet vagy gyomor adenokarcinómája, amely műtéttel nem eltávolítható vagy áttétes, HER2-negatív, ismert PD-L1 CPS értékkel, mérhető vagy értékelhető betegséggel
- Korábbi kezelés
- Nem kaphatott korábban szisztémás kezelést a műtéttel nem eltávolítható vagy áttétes betegségre. A műtét előtti vagy utáni kemoterápia vagy immunterápia megengedett, ha legalább 1 évvel a regisztráció előtt befejeződött.
- Biomarker vagy leletérték
- HER2-negatív adenokarcinóma; a PD-L1 kombinált pozitív pontszámnak (CPS) ismertnek kell lennie (bármilyen CPS érték megengedett)
A részvétel fő kizáró okai
- Terhes vagy szoptató nők
- Kezeletlen, tüneteket okozó agyi áttét
- Korábbi allogén szövet- vagy szervátültetés
- Ismert Gilbert-szindróma vagy ismert homozigóta UGAT1A1*28 polimorfizmus
- Kezdetkor 2-es vagy magasabb fokú perifériás idegkárosodás
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Histologic documentation: HER2 negative adenocarcinoma as defined by American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (Bartley et al., Journal of Clinical Oncology [JCO] 2017) with known PD-L1 combined positive score (CPS) (any CPS is allowed, but should be known prior to registration)
- Stage: unresectable or metastatic
- Tumor site: esophagus, gastroesophageal junction, or stomach
- Measurable disease or non-measurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- No prior systemic treatment for unresectable or metastatic disease
- Prior neoadjuvant or adjuvant cytotoxic chemotherapy or adjuvant immunotherapy is allowed as long as it was completed at least 1 year prior to registration
- Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =< 7 days prior to registration is required
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Absolute neutrophil count (ANC) >= 1,500/mm\^3
- Platelet count >= 100,000/mm\^3
- Creatinine =< 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance >= 30 mL/min
- Total bilirubin =< 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (in patients with liver metastasis: =< 5 x ULN if clearly attributable to liver metastases)
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:; On effective anti-retroviral therapy; Undetectable HIV viral load by standard clinical assay =< 6 months of registration
- No known Gilbert's syndrome or known homozygosity for UGAT1A1*28 polymorphism
- No baseline grade >= 2 peripheral neuropathy, neurosensory toxicity, or neuromotor toxicity per CTCAE version (v) 5.0 regardless of causality
- No medical condition such as uncontrolled infection or uncontrolled diabetes mellitus which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- No untreated, symptomatic brain metastasis. Patients with treated brain metastases are eligible if the following criteria are met: 1) follow-up brain imaging done at least in 4 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression and 2) the patient no longer requires steroids, or is on a stable steroid dose for more than four weeks
- No allogeneic tissue/organ transplant
- Patients who will receive nivolumab in addition to chemotherapy must not have any contraindications to immune checkpoint inhibitors; Patients must not have active autoimmune disease that has required systemic treatment within 6 months prior to registration. Patients are permitted to receive immunotherapy if they have vitiligo, type I diabetes, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event); Patients must not have a condition requiring systemic treatment with either corticosteroids (>10mg/day prednisone equivalents) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids and adrenal replacement doses (=< 10mg/day prednisone equivalent) are permitted; Patients must not have a history of noninfectious pneumonitis requiring steroids; Patients with prior immune mediated adverse events related to immunotherapy that resulted in permanent treatment discontinuation with these agents are ineligible
Ez a vizsgálat jelenleg itt érhető el: Puerto Rico.
Még 1 másik országban, 795 helyszínen
- Cancer Center-Metro Medical Center BayamonBayamón, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Résztvevőt keres
- Puerto Rico Hematology Oncology GroupBayamón, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Résztvevőt keres
- Doctors Cancer CenterManati, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Résztvevőt keres
- Centro Comprensivo de Cancer de UPRSan Juan, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Résztvevőt keres
- PROncologySan Juan, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Résztvevőt keres
- San Juan City HospitalSan Juan, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Résztvevőt keres
- San Juan Community Oncology GroupSan Juan, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) with or without nivolumab for the treatment of patients with advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, or gastric adenocarcinoma. The usual approach for patients who are not in a study is treatment with FOLFOX with some receiving an immunotherapy drug, either nivolumab or pembrolizumab, in addition to FOLFOX chemotherapy. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction. Fluorouracil is in a class of medications called antimetabolites. It stops cells from making DNA and may kill tumor cells. Leucovorin in a class of medications called folic acid analogs. When used with fluorouracil it enhances the effects of this chemotherapy drug. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair, and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Some patients on this trial will receive nivolumab, in addition to mFOLFOX or mFOLFIRINOX chemotherapy. mFOLFIRINOX with or without nivolumab may be more effective than mFOLFOX with or without nivolumab by shrinking the tumor in patients with advanced, unresectable, or metastatic HER2-negative esophageal, gastroesophageal junction, or gastric adenocarcinoma.
A vizsgálat 2 csoportja
- Arm I (mFOLFIRINOX, nivolumab)A vizsgált kezelés
Patients receive fluorouracil IV over 44-46 hours on day 1 of each cycle, leucovorin calcium as bolus injection or IV infusion over 10-120 minutes on day 1 of each cycle, oxaliplatin IV over 2-6 hours on day 1 for up to 12 cycles, and irinotecan IV over 90 minutes on day 1 of each cycle. Patients may also receive nivolumab IV over 30 minutes on day 1 of each cycle as clinically indicated. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study.
Kezelés: Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection és Questionnaire Administration
- Arm II (mFOLFOX, nivolumab)Már használt kezelés, összehasonlításként
Patients receive fluorouracil IV bolus and IV infusion over 44-46 hours on day 1 of each cycle, leucovorin calcium as bolus injection or IV infusion over 10-120 minutes on day 1 of each cycle, and oxaliplatin IV over 2-6 hours on day 1 for up to 12 cycles. Patients may also receive nivolumab IV over 30 minutes on day 1 of each cycle as clinically indicated. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study. Patients are followed every 6 months until 3 years following registration, or at the time of tumor progression, withdrawal or removal from the study.
Kezelés: Fluorouracil, Leucovorin Calcium, Oxaliplatin, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection és Questionnaire Administration
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2026. november 3.